Bass Wins Review Of Ampyra Patents, Denied Enbrel
This article was originally published in Scrip
Executive Summary
Shares of Acorda Therapeutics Inc. tumbled 10.7% on March 11 after word came late in the day the Patent Trial and Appeal Board (PTAB) of the US Patent & Trademark Office agreed to review four of the firm's patents on its FDA-approved multiple sclerosis drug Ampyra (dalfampridine) in response to so-called inter partes review (IPR) petitions filed by hedge fund manager Kyle Bass through his Coalition for Affordable Drugs.